Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Launches Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.